Biopharm Stock on the Move; Repligen recovers on Positive Phase III Results

Repligen Corporation (NASDAQ: RGEN) shares are on the move toward the green shortly after the company reported positive top-line results from a phase III study to evaluate the safety and efficacy of its pancreatic imaging agent RG1068. RGEN trading was halted in the morning of March 14 and resumed at 10.20 a.m. at $3.38, down 7.4% from March 13 closing - Continue Reading »

China MediaExpress Uncertainty; Could Upcoming 10-K help Weather the Storm?

China MediaExpress Holdings’ (Nasdaq: CCME) shares plunged 4.3%, to $11.88 before the trading was suspended shortly after the session started on March 11. The trading was halted pending CCME’s release of material news. However, the company did not release any material information during the last weekend, generating additional uncertainties for investors. - Continue Reading »

Jumpstart; Ener1 Surges at Opening Bell on Triple-digit Revenue Growth, Narrowed Losses

Ener1 Inc. (Nasdaq: HEV) shares soared 16% this morning after the company reported record revenue and shrinking losses in Q4 2010. Despite the strong growth, HEV’s shares plunged 29% over the last year, as the market has concerns about the company’s ability of deploying the production of lithium ion batteries to a profitable level before running out of cash. With - Continue Reading »

FDA News; Cell Terapeutics stumbles on Delay in Pixantrone Approval

Cell Therapeutics Inc. (Nasdaq: CTIC) slipped nearly 2% this morning shortly after the company reported that its appeal to the U.S. Food and Drug Administration (FDA) for pixantrone in aggressive non-Hodgkin’s lymphoma would be ruled in the second quarter of 2011. Following discussions with the FDA, Cell Therapeutics announced a new clinical trial of pixantrone, which could likely postpone the - Continue Reading »

Moment of truth: Human Genome Sciences: Blockbuster Drug Candidate awaits FDA Verdict

Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) have swung up and down around $25.50 since November when the U.S. Food and Drug Administration (FDA) advisory panel voted 13-2 to recommend the approval of the company’s systemic lupus erythematosus  (lupus) drug, Benlysta. The FDA required more information on Benlysta and scheduled the final ruling by March 10, 2011. With a - Continue Reading »

Stock on Top; Jazz Pharmaceuticals surges on Record Results and Superior Outlook

The shares of Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) hit a new record in the after-hours session on March 7, after the company reported strong results for Q4 2010 and posted a guidance for 2011, which topped the market estimates. JAZZ closed the regular session at $27.30 and surged 5.5% to $28.79 in the extended action. - Continue Reading »

Stock Alert – Litigation with Evolution Capital still weighs down CDC Corporation

The shares of CDC Corporation (NASDAQ: CHINA) increased 11% to $3.10 in the afterhours session on March 4, gaining nearly 2% to trade at $2.84 this morning, moving on insignificant trading volume. There was no news to support this appreciation, which we regard to the volatility of small-cap stocks. The company closed the March 4 regular session at $2.79 on - Continue Reading »

Top Biopharm Alert – Allos Therapeutics Rebounds on Potential Expansion of Folotyn Reach

Allos Therapeutics Inc. (NASDAQ: ALTH) soared 6.45% to $3.30 during the afterhours session yesterday, gaining nearly 5% in today’s early trading as the company’s results for Q4 2010 run above the analyst expectations. In addition, Allos announced that the Food and Drug Administration (FDA) agreed on phase III clinical trial of its lead drug Folotyn in patients with previously undiagnosed - Continue Reading »

Top Energy Stock; Lucas Energy Dips 7% after Surging on Completion of the Second Eagle Ford Well

Shares of Lucas Energy Inc. (AMEX: LEI) dropped 7% this morning after surging 79%  yesterday after the company announced the completion of the second Eagle Ford horizontal well in Gonzales County, Texas. The Hagen EF No.2H well is expected to be put on production in a few weeks and the company anticipates it to meet or exceed expectations of 500 - Continue Reading »

Top Energy Stock; ENER Rallies on alarming Solar Incentives Policies

Shares of Energy Conversion Devices Inc. (Nasdaq: ENER) began rebounding from yesterday’s 6.6% plunge that took the stock to a record low of $3.63, inching up 1% to $3.70 this morning. Yesterday’s plunge folowed increasing concerns that the subsidies to boost the solar panel installations in the European Union countries might be frozen.  The company previously reported that the majority - Continue Reading »